The FDA has scheduled an Advisory Committee meeting for July 29, 2026 to review Deramiocel, Capricor’s investigational cell therapy for Duchenne muscular dystrophy. The meeting will be held in person with the option to participate and watch virtually, with a live stream available for public viewing.
The Duchenne community is actively working together to prepare for this important meeting. Following the announcement, PPMD convened Duchenne advocacy partners to align on how we can collaborate and deliver a clear, unified message about the urgent unmet need in Duchenne and the potential role of new therapies like Deramiocel.
We need your voice on July 29th. Join us in ensuring that patient, caregiver, and scientific perspectives are fully represented to help inform FDA and its Advisory Committee as they evaluate this therapy. Whether you plan to submit written testimony or participate in public testimony efforts, our community is strongest when we work together.
Please visit PPMD’s blog post to learn more about how to submit a written testimony.